> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Panel to Mull Covid Vaccine Strain Selection
- URL: https://www.fdaweb.com/fda-panel-to-mull-covid-vaccine-strain-selection/
- Published: 2025-05-07T12:00:00.000Z
- Updated: 2026-09-14T15:11:13.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5159140

FDA is announcing a 5/22 Vaccines and Related Biological Products Advisory Committee meeting to discuss and make recommendations on the selection of the 2025-2026 formula for Covid-19 vaccines for use in the U.S.

The meeting should shed some light on how FDA intends to regulate Covid-19 vaccines amid growing concern that the agency, under HHS secretary **Robert F. Kennedy Jr.’s** leadership, may adopt a more skeptical approach on vaccine approvals. It will also likely be one of the first public appearances of former University of California, San Francisco professor and now CBER director **Vinay Prasad**, a vocal FDA-industry critic ([see story](https://www.fdaweb.com/vinay-prasad-tapped-as-new-cber-director/)).

Prasad has also been very critical of FDA’s response to the Covid-19 pandemic, including its authorization for boosters in children. He also has previously supported randomized placebo-controlled trials for the Covid vaccines to be used every year, a potential impediment FDA commissioner **Marty Makary** is contemplating ([see story](https://www.fdaweb.com/placebo-controlled-trials-needed-for-vaccines-hhs/)).